Makers Laboratories Ltd. Announces Leadership Changes and Q1 Financial Results
Makers Laboratories Ltd. provided an update on its organizational structure and presented its Unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026, following a Board meeting held in Mumbai. The company also detailed internal restructuring related to leadership transitions within its directorship.Directorship Changes and Board Composition
The company confirmed that Mr. Saahil Parikh, who was serving as Whole-time Director/CEO, will not be reappointed for that position due to personal and professional reasons. His term as CEO concluded on August 10, 2026.In light of this transition, the Board has appointed Mr. Parikh as a Non-Executive, Non-Independent Director effective August 11, 2026, pending shareholder approval.
Mr. Saahil Parikh is 51 years old and holds a graduation in Bio-Chemistry from Gujarat University and a Diploma in Management Studies from Ahmedabad Management Association. He possesses approximately 25 years of experience within the pharmaceutical industry, spanning pharma production, quality control, projects, and general management. He is not related to any other Director or Key Managerial Personnel.
Revised Board Structure
Effective August 11, 2026, the composition of Makers Laboratories Ltd.'s Board of Directors has been revised as follows:| Director Name | Designation |
|---|---|
| Mr. R. K. P. Verma | Chairman, Independent Director |
| Ms. Dipti Shah | Independent Director |
| Mr. Vishal Jain | Independent Director |
| Mr. Prashant Godha | Non-Executive, Non-Independent Director |
| Mr. Saahil Parikh | Non-Executive, Non-Independent Director |
| Mr. Nilesh Jain | Executive, Whole-time Director |
The Board has also re-constituted key committees:
- Stakeholders Relationship Committee: Mr. R. K. P. Verma, Mr. Vishal Jain, and Mr. Saahil Parikh.
- Risk Management Committee: Mr. Saahil Parikh, Mr. Nilesh Jain, and Mr. Sandeep Kadam (Sr. Manager/CFO).
Financial Performance Highlights
The company disclosed Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.Standalone Unaudited Financial Results
Key financial performance metrics for Makers Laboratories Ltd. are presented below:
| Particulars | Quarter Ended 30.06.2026 (Unaudited) | Quarter Ended 31.03.2026 (Unaudited) | Quarter Ended 30.06.2025 (Unaudited) | Year Ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 1,018.75 Lacs | 1,127.46 Lacs | 1,372.68 Lacs | 5,034.73 Lacs |
| Total Income | 1,025.90 Lacs | 1,129.92 Lacs | 1,376.58 Lacs | 5,094.01 Lacs |
| Total Expenses | 1,151.62 Lacs | 1,246.04 Lacs | 1,406.53 Lacs | 5,295.14 Lacs |
| Profit/(Loss) Before Tax | (125.72) Lacs | (116.12) Lacs | (29.95) Lacs | (201.13) Lacs |
| Net Profit/(Loss) from Continuing Operations | (107.50) Lacs | (96.37) Lacs | (27.20) Lacs | (171.98) Lacs |
Consolidated Unaudited Financial Results
The consolidated results reflect two reportable segments: 'Pharmaceutical' and 'Chemical Manufacturing'.
| Particulars | 30-Jun-26 (Unaudited) | 31-Mar-26 (Unaudited) | 30-Jun-25 (Unaudited) | 31-Mar-26 (Audited) |
|---|---|---|---|---|
| Segment Revenue | ||||
| Pharmaceutical | 1,025.90 Lacs | 1,129.92 Lacs | 1,376.58 Lacs | 5,041.51 Lacs |
| Chemical Manufacturing | 3,312.19 Lacs | 2,521.34 Lacs | 2,150.13 Lacs | 9,188.93 Lacs |
| Total Income | 4,338.09 Lacs | 3,651.26 Lacs | 3,526.71 Lacs | 14,230.44 Lacs |
| Net Profit/(Loss) after tax (including NCI) | 150.43 Lacs | 109.35 Lacs | 43.67 Lacs | 235.13 Lacs |
The segmental results for the first quarter ended June 30, 2026, showed a PBT of (125.74) Lacs for the Pharmaceutical segment and 755.23 Lacs for Chemical Manufacturing, contributing to a total Q1 PBT of 629.49 Lacs.
Stock Price Movement
Makers Laboratories shares are ticking up this morning as of 12:05, trading at ₹178.00 and reflecting a substantial +7.29% increase. The equity experienced wide intraday movement, fluctuating between a low of ₹165.90 and a high of ₹179.40.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: